Prostate cancer, which is one of the most common diseases in men today, can be diagnosed early with the developing technology. Urology Specialist Prof. Dr. Gökhan Gökçe said that MR-US Fusion Biopsy facilitates the early diagnosis of prostate cancer by 95 percent compared to the traditional method. Medicana Sivas Hospital Urology Specialist Prof. Dr. Gökhan Gökçe stated that the importance of early diagnosis in prostate cancer has also increased and said, “In addition to the elevation of PSA (Prostate Specific Antigen) in the diagnosis of prostate cancer, traditionally biopsies taken from various parts of the prostate with the help of TRUS (Transrectal Ultrasound) are evaluated. MR-US Fusion Biopsy, which was developed against the possibility of missing small foci in biopsies taken from random places, is performed with advanced technology devices and software.
THIS METHOD DOES NOT REQUIRE HOSPITAL INSURANCE
prof. Dr. Gökhan Gökçe said that the most important advantage of MR-US Fusion Biopsy is that it enables targeted biopsy, and said, “Fusion biopsy, also known as smart biopsy, combines the superior aspects of both MR and TRUS methods, allowing early diagnosis in prostate cancer and provides 70 percent of traditional methods. The diagnosis success rate, which is around -75, increases to 95 percent. In this way, the number of pieces taken is less, which reduces the possibility of infection-related complications. Moreover, the method can be completed without the need for hospitalization.”
“THE EARLY DIAGNOSIS CAN GET FULL HEALING WITH APPROPRIATE TREATMENT”
Emphasizing that MR-US Fusion Biopsy detects cancer-suspicious foci with millimetric precision, Prof. Dr. Gökçe said, “Current methods in cancer diagnosis aim to detect millimetric cancer foci early. Thanks to early diagnosis, full recovery can be achieved with appropriate treatment. Developed for this purpose, MR-US Fusion Biopsy detects cancer-suspected foci in prostate biopsy with millimetric precision. MR-US Fusion Biopsy, whose use is increasing worldwide, facilitates the detection of pathological foci with suspected cancer in the prostate with advanced technological devices and software. This method offers the following advantages compared to the traditional method, it allows biopsy from foci that cannot be detected normally, with millimetric precision. It reduces the possibility of repeat biopsy. It increases the rate of early diagnosis.”
FOCUS ARE DETECTED WITH PRECISE PRECISION
Stating that the images obtained from the prostate MR-TRUS Fusion device are converted into 3D, Prof. Dr. Gökçe said, “In MR-US Fusion Biopsy, Magnetic Resonance (MR) images of the prostate are processed with a special software program and combined with real-time TRUS images. Advanced MR technology provides better images of the prostate tissue, so suspicious foci can be detected with a more precise sensitivity. Then, the images obtained from the Prostate MR-TRUS Fusion device are converted into 3D. Images from both MR and TRUS are superimposed and fusion is achieved. A biopsy needle attached to a robotic arm is guided by its navigation feature, allowing targeted biopsy from pathological foci. If cancer foci are detected as a result of the biopsy, the treatment approach is decided according to the findings.” said.